Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173679
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Arias Barquet, Lluís | - |
dc.date.accessioned | 2021-02-04T15:56:25Z | - |
dc.date.available | 2021-02-04T15:56:25Z | - |
dc.date.issued | 2010-04-26 | - |
dc.identifier.issn | 1177-5467 | - |
dc.identifier.uri | http://hdl.handle.net/2445/173679 | - |
dc.description.abstract | Purpose: evaluate the efficacy of pegaptanib, a selective anti-vascular endothelial growth factor (VEGF) agent, and bevacizumab, a nonselective anti-VEGF agent, for retinal pigment epithelial detachment (PED) associated with occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: prospective, comparative, nonrandomized pilot study included patients with PED comprising >50% of total lesion in subfoveal location with visual acuity (VA) 20/40-20/400 and lesions either previously untreated or treated only with photodynamic therapy/verteporfin. Seven patients received pegaptanib 0.3 mg intravitreally (IVT); eight received IVT bevacizumab 1.25 mg. Follow-up occurred every 4-6 weeks for 6 months. Reinjection of initial medication occurred if there was intra- or subretinal fluid observed by optical coherence tomography (OCT) or increased PED. Endpoints were mean changes from baseline to month 6 in VA (ETDRS) and foveal thickness. Results: at baseline, mean VA was lower, and mean foveal thickness was greater in pegaptanib versus bevacizumab-treated patients (36.1 vs 49.5 letters; 470.4 vs 321.1 mum). Mean improvements to month 6 in VA and foveal thickness were greater for pegaptanib (VA: +9.1 vs +7.2 letters; foveal thickness: -88.2 vs -52.9 mum). On average, pegaptanib-treated patients had slower but more sustained improvement in VA and foveal thickness; bevacizumab-treated patients showed rapid improvement with a slow return towards baseline. Both agents were well tolerated. Conclusion: intravitreal injections of pegaptanib or bevacizumab are both efficacious and safe treatments for PED associated with occult CNV secondary to AMD. | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Dove Medical Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.2147/OPTH.S9307 | - |
dc.relation.ispartof | Clinical Ophthalmology, 2010, vol. 26, num. 4, p. 369-374 | - |
dc.relation.uri | https://doi.org/10.2147/OPTH.S9307 | - |
dc.rights | cc-by-nc (c) Arias Barquet, Lluís, 2010 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Malalties de la retina | - |
dc.subject.classification | Angiogènesi | - |
dc.subject.classification | Degeneració (Patologia) | - |
dc.subject.other | Retinal diseases | - |
dc.subject.other | Neovascularization | - |
dc.subject.other | Degeneration (Pathology) | - |
dc.title | Treatment of retinal pigment epithelial detachment with antiangiogenic therapy | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 706664 | - |
dc.date.updated | 2021-02-04T15:56:25Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 20463807 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
706664.pdf | 3.36 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License